Anemia in the intensive care unit

Canadian Journal of Anesthesia

Volumn 50, Issue 6 SUPPL., 2003, Pages

  Vincent, Jean Louis ^a   Sakr, Yasser ^a   Creteur, Jacques ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; ASCORBIC ACID; ERYTHROPOIETIN; FOLIC ACID; HEMOGLOBIN; HISTAMINE H2 RECEPTOR ANTAGONIST; IRON; PLACEBO; RECOMBINANT ERYTHROPOIETIN; SUCRALFATE;

ANEMIA; BLEEDING; BLOOD; BLOOD TRANSFUSION; CLINICAL TRIAL; CRITICAL ILLNESS; ERYTHROCYTE; ERYTHROPOIESIS; GASTROINTESTINAL HEMORRHAGE; HEMOGLOBIN DETERMINATION; HEMOLYSIS; HUMAN; INTENSIVE CARE UNIT; PATHOPHYSIOLOGY; PHYSIOLOGY; PNEUMONIA; PRIORITY JOURNAL; REVIEW; STRESS ULCER;

ANEMIA; CRITICAL ILLNESS; ERYTHROCYTES; HEMORRHAGE; HUMANS; INTENSIVE CARE UNITS;

EID: 0042035624     PISSN: 0832610X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. von Ahsen N, Muller C, Serke S, Frei U, Eckardt KU. Important role of nondiagnostic blood loss and blunted erythropoietic response in the anemia of medical intensive care patients. Crit Care Med 1999; 27: 2630-9.
2. Vincent JL, Baron JF, Rheinhart K, Gattinoni L, Thijs LG, Webb A. Anemia and blood transfusion in critically ill patients. JAMA 2002; 288: 1499-507.
3. Hebert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med 1999; 340: 409-17.
4. Greenburg AG. Pathophysiology of anemia. Am J Med 1996; 101: 7S-11S.
5. Erslev AJ. Clinical manfestations and classification of erythrocyte disorders. In: Beutler B, Lichtman MA, Coller BS, Kipps TJ, (Eds.). Williams Hematology. New York: McGraw Hill; 1994: 441-7.
6. Cook D, Heyland D, Griffith L, Cook R, Marshall J, Pagliarello J. Risk factors for clinically important upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian critical care trials group. Crit Care Med 1999; 27: 2812-7.
7. Pimentel M, Roberts DE, Bernstein CN, Hoppensack M, Duerksen DR. Clinically significant gastrointestinal bleeding in critically ill patients in an era of prophylaxis. Am J Gastroenterol 2000; 95: 2801-6.
8. Devlin JW, Ben Menachem T, Ulep SK, Peters MJ, Fogel RP, Zarowitz BJ. Stress ulcer prophylaxis in medical ICU patients: annual utilization in relation to the incidence of endoscopically proven stress ulceration. Ann Pharmacother 1998; 32: 869-74.
9. Czaja AJ, McAlhany JC, Pruitt BA Jr. Acute gastroduodenal disease after thermal injury. An endoscopic evaluation of incidence and natural history. N Engl J Med 1974; 291: 925-9.
10. Schiessel R, Starlinger M, Wolf A, et al. Failure of cimetidine to prevent gastroduodenal ulceration and bleeding after renal transplantation. Surgery 1981; 90: 456-8.
11. Corwin HL, Parsonnet KC, Gettinger A. RBC transfusion in the ICU. Is there a reason? Chest 1995; 108: 767-71.
12. Andrews T, Waterman H, Hillier V. Blood gas analysis: a study of blood loss in intensive care. J Adv Nurs 1999; 30: 851-7.
13. Smoller BR, Kruskall MS. Phlebotomy for diagnostic laboratory tests in adults. Pattern of use and effect on transfusion requirements. N Engl J Med 1986; 314: 1233-5.
14. O'Hare D, Chilvers RJ. Arterial blood sampling practices in intensive care units in England and Wales. Anaesthesia 2001; 56: 568-71.
15. Mitchell RB, Hoffman PC. Anemia, leukopenia, and elevated blood counts. In: Hall JB, Schmidt GA, Wood LD, (Eds.). Principles of Critical Care. New York: McGraw-Hill Inc; 1992: 1807-17.
16. Gauvin F, Toledano B, Champagne J, Lacroix J. Reactive hemophagocytic syndrome presenting as a component of multiple organ dysfunction syndrome. Crit Care Med 2000; 28: 3341-5.
17. Francois B, Trimoreau F, Vignon P, Fixe P, Praloran V, Gastinne H. Thrombocytopenia in the sepsis syndrome: role of hemophagocytosis and macrophage colony-stimulating factor. Am J Med 1997; 103: 114-20.
18. Reiner AP, Spivak JL. Hematophagic histiocytosis. A report of 23 new patients and a review of the literature. Medicine (Baltimore) 1988; 67: 369-88.
19. Streiff RR. Anemia and nutritional deficiency in the acutely ill hospitalized patients. Med Clin North Am 1993; 77: 911-89.
20. Rodriguez RM, Corwin HL, Gettinger A, Corwin MJ, Gubler D, Pearl RG. Nutritional deficiencies and blunted erythropoietin response as causes of the anemia of critical illness. J Crit Care 2001; 16: 36-41.
21. Patteril MV, Davey-Quinn AP, Gedney JA, Murdoch SD, Bellamy MC. Functional iron deficiency, infection and systemic inflammatory response syndrome in critical illness. Anaesth Intensive Care 2001; 29: 473-8.
22. Schobersberger W, Hobisch-Hagen P, Fuchs D, Hoffmann G, Jelkmann W. Pathogenesis of anaemia in the critically ill patient. Clin Intensive Care 1998; 9: 111-7.
23. Schuster SJ, Koury ST, Bohrer M, Salceda S, Caro J. Cellular sites of extrarenal and renal erythropoietin production in anaemic rats. Br J Haematol 1992; 81: 153-9.
24. Adamson JW. Regulation of red blood cell production. Am J Med 1996; 101: 4S-6S.
25. Erslev AJ, Caro J, Miller O, Silver R. Plasma erythropoietin in health and disease. Ann Clin Lab Sci 1980; 10: 250-7.
26. van Iperen CE, Biesma DH, van de Wiel A, Marx JJ. Erythropoietic response to acute and chronic anaemia: focus on postoperative anaemia. Br J Anaesth 1998; 81(Suppl 1): 2-5.
27. Krafte-Jacobs B, Levetown ML, Bray GL, Ruttimann UE, Pollack MM. Erythropoietin response to critical illness. Crit Care Med 1994; 22: 821-6.
28. Rogiers P, Zhang H, Leeman M, et al. Erythropoietin response is blunted in critically ill patients. Intensive Care Med 1997; 23: 159-62.
29. van Iperen CE, Gaillard CA, Kraaijenhagen RJ, Braam BG, Marx JJ, van de WA. Response of erythropoiesis and iron metabolism to recombinant human erythropoietin in intensive care unit patients. Crit Care Med 2000; 28: 2773-8.
30. Hobisch-Hagen P, Wiedermann F, Mayr A, et al. Blunted erythropoietic response to anemia in multiply traumatized patients. Crit Care Med 2001; 29: 743-7.
31. Johnson CS, Cook CA, Turmanski P. In vivo suppression of erythropoiesis by tumor necrosis factor-alpha (TNF-alpha): reversal with exogenous erythropoietin (EPO). Exp Hematol 1990; 18: 109-13.
32. Leng HM, Kidson SH, Keraan MM, Randall GW, Folb PI. Cytokine-mediated inhibition of erythropoietin synthesis by dexamethasone. J Pharm Pharmacol 1996; 48: 971-4.
33. Jelkmann W, Pagel H, Wolff M, Fandrey J. Monokines inhibiting erythropoietin production in human hepatoma cultures and in isolated perfused rat kidneys. Life Sci 1992; 50: 301-8.
34. Roodman GD, Bird A, Hutzler D, Montgomery W. Tumor necrosis factor-alpha and hematopoietic progenitors: effects of tumor necrosis factor on the growth of erythroid progenitors CFU-E and BFU-E and the hematopoietic cell lines K562, HL60, and HEL cells. Exp Hematol 1987; 15: 928-35.
35. Taniguchi S, Dai CH, Krantz SB. Specific binding of interferon-gamma to high affinity receptors on human erythroid colony-forming cells. Exp Hematol 1997; 25: 193-8.
36. Dybedal I, Jacobsen SE. Transforming growth factor beta (TGF-beta), a potent inhibitor of erythropoiesis: neutralizing TGF-beta antibodies show erythropoietin as a potent stimulator of murine burst-forming unit erythroid colony formation in the absence of a burst-promoting activity. Blood 1995; 86: 949-57.
37. Tracey KJ, Wei H, Manogue KR, et al. Cachectin/tumor necrosis factor induces cachexia, anemia and inflammation. J Exp Med 1988; 167: 1211-74.
38. Miller KL, Carlino JA, Ogawa Y, Avis PD, Carroll KG. Alterations in erythropoiesis in TGF-beta 1-treated mice. Exp Hematol 1992; 20: 951-6.
39. Johnson CS, Keckler DJ, Topper MI, Braunschweiger PG, Furmanski P. In vivo hematopoietic effects of recombinant interleukin-1 alpha in mice: stimulation of granulocytic, monocytic, megakaryocytic, and early erythroid progenitors, suppression of late-stage erythropoiesis, and reversal of erythroid suppression with erythropoietin. Blood 1989; 73: 678-83.
40. Smoller BR, Kruskall MS, Horowitz GL. Reducing adult phlebotomy blood loss with the use of pediatric-sized blood collection tubes. Am J Clin Pathol 1989; 91: 701-3.
41. Gleason E, Grossman S, Campbell C. Minimizing diagnostic blood loss in critically ill patients. Am J Crit Care 1992; 1: 85-90.
42. Silver MJ, Li YH, Gragg LA, Jubran F, Stoller JK. Reduction of blood loss from diagnostic sampling in critically ill patients using a blood-conserving arterial line system. Chest 1993; 104: 1711-5.
43. Messori A, Trippoli S, Vaiani M, Gorini M, Corrado A. Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for prevention of stress ulcer: meta-analysis of randomised controlled trials. Br Med J 2000; 321: 1103-6.
44. Cook DJ, Reeve BK, Guyatt GH, et al. Stress ulcer prophylaxis in critically ill patients. JAMA 1996; 275: 308-14.
45. Cook D, Guyatt G, Marshall J, et al. A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. N Engl J Med 1998; 338: 791-7.
46. Nelson AH, Fleisher LA, Rosenbaum SH. Relationship between postoperative anemia and cardiac morbidity in high-risk vascular patients in the intensive care unit. Crit Care Med 1993; 21: 860-6.
47. Hebert PC, Wells G, Tweeddale M, et al. Does transfusion practice affect mortality in critically ill patients? Transfusion Requirements in Critical Care (TRICC) Investigators and the Canadian Critical Care Trials Group. Am J Respir Crit Care Med 1997; 155: 1618-23.
48. Hebert PC, Yetisir E, Martin C, et al. Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases? Crit Care Med 2001; 29: 227-34.
49. Hebert PC, Wells G, Martin C, et al. A Canadian survey of transfusion practices in critically ill patients. Transfusion requirements in critical care investigators and the Canadian critical care trials group. Crit Care Med 1998; 26: 482-7.
50. Marik PE, Sibbald WJ. Effect of stored-blood transfusion on oxygen delivery in patients with sepsis. JAMA 1993; 269: 3024-9.
51. Begue S. Leukocyte depletion. Transfus Clin Biol 1998; 5: 411-4.
52. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987; 316: 73-8.
53. Gabriel A, Kozek S, Chiari A, et al. High-dose recombinant human erythropoietin stimulates reticulocyte production in patients with multiple organ dysfunction syndrome. J Trauma 1998; 44: 361-7.
54. Still JM Jr, Belcher K, Law EJ, et al. A double-blinded prospective evaluation of recombinant human erythropoietin in acutely burned patients. J Trauma 1995; 38: 233-6.
55. Corwin HL, Gettinger A, Rodriguez RM, et al. Efficacy of recombinant human erythropoietin in the critically ill patient: a randomized, double-blind, placebo-controlled trial. Crit Care Med 1999; 27: 2346-50.
56. Corwin HL, Gettinger A, Pearl RG, et al. Efficacy of recombinant human erythropoietin in critically ill patients. JAMA 2002; 288: 2827-35.